The impact of hypoxia on oncolytic virotherapy

Virus Adaptation and Treatment

Volumn 3, Issue 1, 2011, Pages 71-82

  Sheng Guo, Z ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Combination strategy; HIF; Hypoxia; Macrophage; Oncolysis; Oncolytic virus; Viral replication; Viral spread

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VIRUS PROTEIN; VON HIPPEL LINDAU PROTEIN;

ADENOVIRUS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL METABOLISM; CELL SURVIVAL; CYTOTOXICITY; DNA STRUCTURE; ENCEPHALOMYOCARDITIS VIRUS; GENE CONTROL; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HUMAN; HYPOXIA; HYPOXIA RESPONSIVE ELEMENT; KIDNEY CANCER; MACROPHAGE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROTEIN SYNTHESIS; REOVIRUS; REVIEW; TISSUE NECROSIS; TRANSGENE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

EID: 84855255095     PISSN: None     EISSN: 11791624     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651-659.
2. Cattaneo R, Miest T, Shashkova E V, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008;6(7):529-540.
3. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008;1785(2):217-231.
4. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009; 9(1):64-71.
5. Kaur B, Cripe T P, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther. 2009;9(5):341-355.
6. Guo ZS, Parimi V, O'Malley ME, et al. The combination of immu-nosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther. 2010;17(12): 1465-1475.
7. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 2010; 21(2-3): 91-98.
8. Thorne SH, Liang W, Sampath P, et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell- oncolytic virus combination therapy. Mol Ther. 2010;18(9):1698-1705.
9. Wongthida P, Diaz RM, Pulido C, et al. Activating systemic T cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther. 2011; April 11. [Epub ahead of print.]
10. Mahoney DJ, Stojdl D F. Potentiating oncolytic viruses by targeted drug intervention. Curr Opin Mol Ther. 2010;12(4):394-402.
11. Rowan K. Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst. 2010;102(9):590-595.
12. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005-4015.
13. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941-949.
14. Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther. 2011;19(6):1170-1179.
15. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99-102.
16. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007;7(2):141-148.
17. Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther. 2008;10(1):32-37.
18. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 2010;21(2-3):127-134.
19. De Silva N, Atkins H, Kirn DH, Bell JC, Breitbach CJ. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. Cytokine Growth Factor Rev. 2010;21(2-3):135-141.
20. Hay JG. The potential impact of hypoxia on the success of oncolytic virotherapy. Curr Opin Mol Ther. 2005;7(4):353-358.
21. Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009;20(10):1119-1132.
22. Boisgerault N, Tangy F, Gregoire M. New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy. 2010;2(2):185-199.
23. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18(2):251-263.
24. Roberts MS, Lorence RM, Groene WS, Bamat MK. Naturally oncolytic viruses. Curr Opin Mol Ther. 2006;8(4):314-321.
25. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003;77(16): 8843-8856.
26. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263-275.
27. Wang F, Ma Y, Barrett J W, et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol. 2004;5(12):1266-1274.
28. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol. 2011;85(12):6015-6023.
29. Bauzon M, Hermiston T W. Oncolytic viruses: the power of directed evolution. Adv Virol. 2012; article no. 586389. doi:10.1155/2012/ 586389.
30. Kuhn I, Harden P, Bauzon M, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3(6):e2409.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
32. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49(23):6449-6465.
33. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904-5912.
34. Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvi-ronment modulation on the effcacy of oncolytic virus therapy. J Natl Cancer Inst. 2007;99(23):1768-1781.
35. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93(4): 266-276.
36. Martinive P, Defresne F, Bouzin C, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 2006;66(24):11736-11744.
37. Matsumoto S, Yasui H, Mitchell JB, Krishna MC. Imaging cycling tumor hypoxia. Cancer Res. 2010;70(24):10019-10023.
38. Lin Q, Cong X, Yun Z. Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha. Mol Cancer Res. 2011; 9(6):757-765.
39. Wenger RH. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol. 2000;203(Pt 8):1253-1263.
40. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441(7092): 437-443.
41. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8(11): 851-864.
42. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009;28(45):3949-3959.
43. Hashimoto O, Shimizu K, Semba S, et al. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. Pathobiolog y. 2011;78(4):181-192.
44. Heddleston JM, Wu Q, Rivera M, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. August 12, 2011. [Epub ahead of print.] doi:10.1038/ cdd.2011.109.
45. Zhou Y, Zhou Y, Shingu T, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843-32853.
46. Matsumoto K, Arao T, Tanaka K, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009;69(18):7160-7164.
47. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang C V. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 2001;276(11):7919-7926.
48. Box AH, Demetrick DJ. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis. 2004;25(12):2325-2335.
49. Olcina M, Lecane PS, Hammond EM. Targeting hypoxic cells through the DNA damage response. Clin Cancer Res. 2010;16(23):5624-5629.
50. Young SD, Marshall RS, Hill R P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A. 1988;85(24):9533-9537.
51. Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807-811.
52. Corzo CA, Condamine T, Lu L, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439-2453.
53. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967-975.
54. Imtiyaz HZ, Williams E P, Hickey MM, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor infammation. J Clin Invest. 2010;120(8):2699-2714.
55. Sun X, Cheng G, Hao M, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29(4): 709-722.
56. Doedens AL, Stockmann C, Rubinstein M P, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70(19): 7465-7475.
57. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005;167(3):627-635.
58. Knowles HJ, Harris AL. Macrophages and the hypoxic tumour microen-vironment. Front Biosci. 2007;12:4298-4314.
59. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-237.
60. Sitkovsky M V, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res. 2008;14(19): 5947-5952.
61. Noman MZ, Buart S, Van Pelt J, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol. 2009;182(6):3510-3521.
62. Hasmim M, Noman MZ, Lauriol J, et al. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol. 2011;187(8):4031-4039.
63. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011; 475(7355):226-230.
64. Wilson WR, Hay M P. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
65. Dewhirst M W, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008; 8(6):425-437.
66. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442-458.
67. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191-201.
68. Rohwer N, Dame C, Haugstetter A, et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010;5(8):e12038.
69. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437-447.
70. Kottke T, Hall G, Pulido J, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest. 2010;120(5):1551-1560.
71. Breitbach CJ, De Silva NS, Falls TJ, et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther. 2011;19(5):886-894.
72. Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D. Enhanced specifc delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 2010; 17(4):244-255.
73. Roulston A, Marcellus RC, Branton PE. Viruses and apoptosis. Annu Rev Microbiol. 1999;53:577-628.
74. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted infammation during oncolytic virus therapy severely compromises tumor blood fow. Mol Ther. 2007;15(9):1686-1693.
75. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specifc, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007;4(12):e353.
76. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther. 2002;13(14):1737-1750.
77. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene. 2003; 22(14):2065-2072.
78. Cuevas Y, Hernandez-Alcoceba R, Aragones J, et al. Specifc oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res. 2003;63(20):6877-6884.
79. Cho WK, Seong YR, Lee YH, et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther. 2004;10(5):938-949.
80. Post DE, Devi NS, Li Z, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res. 2004;10(24):8603-8612.
81. Shen BH, Hermiston T W. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 2005;12(11):902-910.
82. Pipiya T, Sauthoff H, Huang YQ, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther. 2005;12(11):911-917.
83. Shen BH, Bauzon M, Hermiston T W. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther. 2006;13(12):986-990.
84. Cherry T, Longo SL, Tovar-Spinoza Z, Post DE. Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor effcacy. Gene Ther. 2010;17(12):1430-1441.
85. Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res. 2006;12(21): 6523-6531.
86. Wang X, Su C, Cao H, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor effcacy on common human solid cancers. Mol Cancer Ther. 2008;7(6):1598-1603.
87. Harvey TJ, Hennig IM, Shnyder SD, et al. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Cancer Gene Ther. 2011;18(11):773-784.
88. Guse K, Diaconu I, Rajecki M, et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic onco-lytic adenovirus for kidney cancer treatment. Gene Ther. 2009;16(8): 1009-1020.
89. Gomes EM, Rodrigues MS, Phadke A P, et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res. 2009;15(4):1317-1325.
90. Post DE, Sandberg EM, Kyle MM, et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 2007;67(14):6872-6881.
91. Kwon OJ, Kim PH, Huyn S, et al. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specifc killing of hepatocellular carcinomas. Clin Cancer Res. 2010;16(24):6071-6082.
92. Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther. 2009;17(1): 51-56.
93. Fasullo M, Burch AD, Britton A. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells. Cell Cycle. 2009;8(14):2194-2197.
94. Longo SL, Griffth C, Glass A, Shillitoe EJ, Post DE. Development of an oncolytic herpes simplex virus using a tumor-specifc HIF-responsive promoter. Cancer Gene Ther. 2011;18(2):123-134.
95. Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 2010;17(2):281-287.
96. Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol. 2004;78(17):8960-8970.
97. Hwang II, Watson IR, Der SD, Ohh M. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol. 2006;80(21):10712-10723.
98. Maxwell PH, Wiesener MS, Chang G W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275.
99. Willmon C, Diaz RM, Wongthida P, et al. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther. 2011;19(1):140-149.
100. Leveille S, Goulet ML, Lichty BD, Hiscott J. VSV oncolytic treatment interferes with tumor associated dendritic cell function and abrogates tumor antigen presentation. J Virol. 2011;85(23): 12160-12169.
101. Cho IR, Koh SS, Min HJ, et al. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther. 2010;17(5):365-372.
102. Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17(4):888-895.
103. Roos FC, Roberts AM, Hwang II, et al. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med. 2010;2(7):275-288.
104. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004;104(8):2224-2234.
105. Qian BZ, Pollard J W. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
106. Muthana M, Giannoudis A, Scott SD, et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 2011;71(5):1805-1815.
107. Baas T. Hypoxic homing in prostate cancer. SciBX. 2011;March 24. doi:10.1038/scibx.2011.1330.
108. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther. 2008;10(4):371-379.
109. Owen MR, Stamper IJ, Muthana M, et al. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res. 2011;71(8):2826-2837.
110. Prestwich RJ, Harrington KJ, Pandha HS, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008; 8(10):1581-1588.
111. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011; 19(6):1008-1016.
112. Pol JG, Resseguier J, Lighty BD. Oncolytic viruses, a step into cancer immunotherapy. Virus Adapt Treat. 2011;3. In press.
113. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427.
114. Qayum N, Muschel RJ, Im JH, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 2009;69(15): 6347-6354.